Alderman S, Kailas S, Goldfarb S, et al. Cholestatic hepatitis after ingestion of chaparral leaf: confirmation by endoscopic retrograde cholangiopancreatography and liver biopsy.
J Clin Gastroenterol.
1994;19:242-247.
[No authors listed]. From the Centers for Disease Control and Prevention. Chaparral-induced toxic hepatitis—California and Texas, 1992.
JAMA.
1992;268:3295,3298.
Gordon DW, Rosenthal G, Hart J, et al. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications.
JAMA.
1995;273:489-490.
Katz M, Saibil F. Herbal hepatitis: subacute hepatic necrosis secondary to chaparral leaf.
J Clin Gastroenterol.
1990;12:203-206.
Smith BC, Desmond PV. Acute hepatitis induced by ingestion of the herbal medication chaparral [letter].
Aust N Z J Med.
1993;23:526.
Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity.
Arch Intern Med.
1997;157:913-919.
Jim LK, Gee JP. Adverse effects of drugs on the liver. In: Young LY, Koda-Kimble MA, eds.
Applied Therapeutics: The Clinical Use of Drugs.
Vancouver, WA: Applied Therapeutics, Inc; 1995:26:1-26.
A to Z Drug Facts
[book on CD-ROM]. 2nd ed. St. Louis, MO: Facts and Comparisons; 2000.
Takanaga H, Ohnishi A, Murakami H, et al. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects.
Clin Pharmacol Ther.
2000;67:201-214.
A to Z Drug Facts
[book on CD-ROM]. 2nd ed. St. Louis, MO: Facts and Comparisons; 2000.
Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety.
Am J Cardiol.
1994;73:25D-29D.
Kashyap ML, Evans R, Simmons PD, et al. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated [abstract].
J Am Coll Cardiol.
2000;35(2 suppl A):A326.
Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q10
during treatment with HMG-CoA reductase inhibitors.
Mol Aspects Med.
1997;18(suppl):S137-S144.
Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.
J Clin Pharmacol.
1993;33:226-229.
Mortensen SA, Vadhanavikit S, Muratsu K, et al. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure.
Int J Tissue React.
1990;12:155-162.
Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q10
during treatment with HMG-CoA reductase inhibitors.
Mol Aspects Med.
1997;18(suppl):S137-S144.
Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10
-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.
J Clin Pharmacol.
1993;33:226-229.
Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans.
Proc Natl Acad Sci USA.
1990;87:8931-8934.
Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans.
Proc Natl Acad Sci USA.
1990;87:8931-8934.
Bargossi AM, Battino M, Gaddi A, et al. Exogenous CoQ10
preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Int J Clin Lab Res.
1994;24:171-176.
Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
Heart.
2001;85:544-548.
Sugimoto Ki K, Ohmori M, Tsuruoka S, et al. Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin.
Clin Pharmacol Ther. 2001;70:518-524.
Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety.
Am J Cardiol.
1994;73:25D-29D.
Kashyap ML, Evans R, Simmons PD, et al. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated.
J Am Coll Cardiol.
2000;35(suppl A):326.
Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia.
Am J Cardiol.
2001;87:476-479.
Wink J, Giacoppe G, King J. Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy.
Am Heart J.
2002;143:514-518.
Stocker R, Pollicino C, Gay CA et al. Neither plasma coenzyme Q(10) concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: A prospective case-control study from the LIPID study.
Atherosclerosis. 2005 Oct 8. [Epub ahead of print]
Sorokin AV, Duncan B, Panetta R, Thompson PD. Rhabdomyolysis associated with pomegranate juice consumption.
Am J Cardiol. 2006;98:705-706.
Meyer BJ, Hammervold T, Rustan AC, et al. Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.
Lipids. 2007;42:109-115.
Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49:2231-2237.
Mabuchi H, Nohara A, Kobayashi J, et al. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: A randomized double-blind study. Atherosclerosis. 2007 Aug 4. [Epub ahead of print]
Strey CH, Young JM, Molyneux SL, et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q(10) reductions in chronic heart failure. Atherosclerosis. 2005;179:201-206.
Andren L, Andreasson A, Eggertsen R. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol. 2007 Aug 15. [Epub ahead of print]
Fan L, Zhang W, Guo D, et al. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther. 2007 Sep 12. [Epub ahead of print]
Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:1354-1367.
Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol. 2007;100:1400-1403.
Last reviewed November 2007 by EBSCO CAM Review Board
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.